Movement Alert|Northrop Grumman Falls 5.75% in Regular Trading, Adjusted EPS Misses Estimates as RBC Slashes Price Target

Market Focus
Jul 21

On July 21, Northrop Grumman fell 5.75% in regular trading, trading at $484.21/share, with turnover of approximately $100 million. The decline was triggered by a combination of adjusted earnings missing consensus and a significant analyst price target cut.

The company reported Q2 adjusted EPS of $6.77, missing the analyst consensus estimate of $6.82 by 0.73%, representing a 4.78% year-over-year decrease from $7.11. While GAAP EPS of $7.68 exceeded FactSet's estimate of $6.84, and sales of $10.876 billion beat the $10.803 billion estimate, the adjusted earnings shortfall weighed on sentiment. The company guided full-year sales of $43.75B-$44.25B, in line with the $44.00B consensus.

On the same day, RBC Capital Markets cut its price target from $750 to $640, a 14.7% reduction, while maintaining its Outperform rating. This follows a series of target price reductions from major institutions in recent months, including Wells Fargo cutting to $620 from $800 and Goldman Sachs lowering to $533 from $603. Peer Lockheed Martin also declined 3.46%, reflecting broad defense sector pressure.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10